JP2011520781A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011520781A5 JP2011520781A5 JP2011503360A JP2011503360A JP2011520781A5 JP 2011520781 A5 JP2011520781 A5 JP 2011520781A5 JP 2011503360 A JP2011503360 A JP 2011503360A JP 2011503360 A JP2011503360 A JP 2011503360A JP 2011520781 A5 JP2011520781 A5 JP 2011520781A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- egf
- ms4a12
- activity
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 27
- 239000003795 chemical substances by application Substances 0.000 claims 17
- 101000578853 Homo sapiens Membrane-spanning 4-domains subfamily A member 12 Proteins 0.000 claims 14
- 102100028425 Membrane-spanning 4-domains subfamily A member 12 Human genes 0.000 claims 14
- 230000000694 effects Effects 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 230000004043 responsiveness Effects 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 230000004941 influx Effects 0.000 claims 5
- 206010027476 Metastases Diseases 0.000 claims 4
- 230000009401 metastasis Effects 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000001301 EGF receptor Human genes 0.000 claims 3
- 108060006698 EGF receptor Proteins 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 230000006369 cell cycle progression Effects 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 238000013508 migration Methods 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 238000009736 wetting Methods 0.000 claims 2
- 230000034196 cell chemotaxis Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 230000035605 chemotaxis Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08007109.5 | 2008-04-10 | ||
| EP08007109A EP2108701A1 (en) | 2008-04-10 | 2008-04-10 | Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing |
| PCT/EP2009/002309 WO2009124670A1 (en) | 2008-04-10 | 2009-03-30 | Methods involving ms4a12 and agents targeting ms4a12 for therapy, diagnosis and testing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011520781A JP2011520781A (ja) | 2011-07-21 |
| JP2011520781A5 true JP2011520781A5 (enExample) | 2012-05-24 |
Family
ID=39811474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011503360A Pending JP2011520781A (ja) | 2008-04-10 | 2009-03-30 | 治療、診断及び検査のためのｍｓ４ａ１２を伴う方法、及びｍｓ４ａ１２を標的とする剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110027297A1 (enExample) |
| EP (2) | EP2108701A1 (enExample) |
| JP (1) | JP2011520781A (enExample) |
| CN (1) | CN101998992A (enExample) |
| AU (1) | AU2009235746A1 (enExample) |
| CA (1) | CA2714997A1 (enExample) |
| NZ (1) | NZ588177A (enExample) |
| WO (1) | WO2009124670A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016135772A1 (ja) * | 2015-02-24 | 2016-09-01 | 株式会社ジーンテクノサイエンス | がんの脳転移の診断、予防及び治療方法、並びに血液脳関門を通過させるための医薬送達システム |
| US11249075B2 (en) | 2016-06-20 | 2022-02-15 | Beckman Coulter, Inc. | Dry-down processes for dye-conjugated reagents |
| US20210122817A1 (en) | 2018-01-31 | 2021-04-29 | Alector Llc | Anti-ms4a6a antibodies and methods of use thereof |
| EP3746476A1 (en) | 2018-01-31 | 2020-12-09 | Alector LLC | Anti-ms4a4a antibodies and methods of use thereof |
| CA3145885A1 (en) * | 2019-07-31 | 2021-02-04 | Jeonghoon Sun | Anti-ms4a4a antibodies and methods of use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
| EP1309726B2 (en) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| DE10211088A1 (de) * | 2002-03-13 | 2003-09-25 | Ugur Sahin | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE10341812A1 (de) * | 2003-09-10 | 2005-04-07 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
-
2008
- 2008-04-10 EP EP08007109A patent/EP2108701A1/en not_active Withdrawn
-
2009
- 2009-03-30 CA CA2714997A patent/CA2714997A1/en not_active Abandoned
- 2009-03-30 EP EP09731038A patent/EP2265718A1/en not_active Withdrawn
- 2009-03-30 NZ NZ588177A patent/NZ588177A/en not_active IP Right Cessation
- 2009-03-30 US US12/937,178 patent/US20110027297A1/en not_active Abandoned
- 2009-03-30 JP JP2011503360A patent/JP2011520781A/ja active Pending
- 2009-03-30 CN CN2009801128194A patent/CN101998992A/zh active Pending
- 2009-03-30 AU AU2009235746A patent/AU2009235746A1/en not_active Abandoned
- 2009-03-30 WO PCT/EP2009/002309 patent/WO2009124670A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Reid et al. | Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer | |
| Guo et al. | Exosomes: Potent regulators of tumor malignancy and potential bio-tools in clinical application | |
| Yang et al. | Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications | |
| Li et al. | Osteopontin RNA aptamer can prevent and reverse pressure overload-induced heart failure | |
| Shen et al. | Post‐transcriptional regulation of the tumor suppressor miR‐139‐5p and a network of miR‐139‐5p‐mediated m RNA interactions in colorectal cancer | |
| Yao et al. | Down-regulation of Krüppel-like factor-4 by microRNA-135a-5p promotes proliferation and metastasis in hepatocellular carcinoma by transforming growth factor-β1 | |
| Matsumoto et al. | Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma | |
| JP2014526456A5 (enExample) | ||
| EP3111937A1 (en) | Medicament for treatment of liver cancer | |
| Zhu et al. | eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma | |
| JP2016540778A5 (enExample) | ||
| Pathak et al. | Role of angiogenesis and its biomarkers in development of targeted tumor therapies | |
| CA2946407A1 (en) | Multiple targeted rnai for the treatment of cancers | |
| Han et al. | TUG1 is involved in liver fibrosis and activation of HSCs by regulating miR-29b | |
| JP2014526450A5 (enExample) | ||
| Wang et al. | Human cancer cells suppress behaviors of endothelial progenitor cells through miR-21 targeting IL6R | |
| JP2011520781A5 (enExample) | ||
| Takiguchi et al. | Involvement of CXCL14 in osteolytic bone metastasis from lung cancer | |
| EP3301176B1 (en) | Method for identifying nucleic acids regulating metastasation | |
| JP2014523398A5 (enExample) | ||
| Hu et al. | Interruption of the long non-coding RNA HOTAIR signaling axis ameliorates chemotherapy-induced cachexia in bladder cancer | |
| Zhou et al. | Long noncoding RNA ZFAS1 promotes hepatocellular carcinoma proliferation by epigenetically repressing miR-193a-3p. | |
| Petrović et al. | Breast cancer response to therapy: Can microRNAs lead the way? | |
| Luo et al. | The function and clinical relevance of lncRNA UBE2CP3-001 in human gliomas | |
| Zheng et al. | Roles of cancer-associated fibroblast functional heterogeneity in shaping the lymphatic metastatic landscape: new insights and therapeutic strategies |